Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-22
2008-04-22
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S399000, C548S110000, C548S314700, C548S336100
Reexamination Certificate
active
10382203
ABSTRACT:
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
REFERENCES:
patent: 3708598 (1973-01-01), Griot
patent: 4024271 (1977-05-01), Durant et al.
patent: 4032522 (1977-06-01), Baldwin et al.
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4356108 (1982-10-01), Schwab et al.
patent: 4873313 (1989-10-01), Crawford et al.
patent: 4933422 (1990-06-01), Hammer et al.
patent: 4963539 (1990-10-01), Delaney et al.
patent: 5011849 (1991-04-01), Gassner et al.
patent: 5153226 (1992-10-01), Chucholowski et al.
patent: 5166214 (1992-11-01), Billheimer et al.
patent: 5179210 (1993-01-01), Ebel et al.
patent: 5192789 (1993-03-01), Lo et al.
patent: 5202424 (1993-04-01), Vlassara et al.
patent: 5318984 (1994-06-01), Billheimer et al.
patent: 5358960 (1994-10-01), Ulrich et al.
patent: 5500436 (1996-03-01), Schonafinger et al.
patent: 5523317 (1996-06-01), Masaki et al.
patent: 5585344 (1996-12-01), Vlassara et al.
patent: 5589496 (1996-12-01), Hamanaka et al.
patent: 5663186 (1997-09-01), Nelson et al.
patent: 5688653 (1997-11-01), Ulrich et al.
patent: 5817823 (1998-10-01), Hong et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 5939526 (1999-08-01), Gaugler et al.
patent: 5962500 (1999-10-01), Eide et al.
patent: 5962535 (1999-10-01), Miyamoto et al.
patent: 6034250 (2000-03-01), Goldstein et al.
patent: 6100098 (2000-08-01), Newkirk et al.
patent: 6197791 (2001-03-01), Venkatesan et al.
patent: 6201002 (2001-03-01), Beere et al.
patent: 6265351 (2001-07-01), La Porta et al.
patent: 6277853 (2001-08-01), Perez et al.
patent: 6300356 (2001-10-01), Segal et al.
patent: 6353009 (2002-03-01), Fujiwara et al.
patent: 6416733 (2002-07-01), Barrett et al.
patent: 6441023 (2002-08-01), Venkatesan et al.
patent: 6441064 (2002-08-01), Shah et al.
patent: 6538013 (2003-03-01), Goebel et al.
patent: 6541639 (2003-04-01), Zhou et al.
patent: 6613801 (2003-09-01), Mjalli et al.
patent: 6673810 (2004-01-01), Lam et al.
patent: 6673927 (2004-01-01), Gordon et al.
patent: 6730796 (2004-05-01), Cheng et al.
patent: 6919338 (2005-07-01), Mortlock et al.
patent: 2001/0039256 (2001-11-01), Stern et al.
patent: 2002/0116725 (2002-08-01), Stern et al.
patent: 2002/0122799 (2002-09-01), Stern et al.
patent: 2003/0207896 (2003-11-01), Konno et al.
patent: 2003/0236282 (2003-12-01), Hernaus et al.
patent: 2004/0127692 (2004-07-01), David et al.
patent: 0 586 806 (1994-03-01), None
patent: 584588 (1994-03-01), None
patent: 633026 (1995-01-01), None
patent: 070700 (1996-04-01), None
patent: 1139990 (2004-05-01), None
patent: 2 005 674 (2005-04-01), None
patent: 06080656 (1994-03-01), None
patent: 09040651 (1997-02-01), None
patent: 2003-012690 (2003-01-01), None
patent: 2003-040888 (2003-02-01), None
patent: 2003-313170 (2003-11-01), None
patent: 2003-313172 (2003-11-01), None
patent: 2004-221557 (2004-08-01), None
patent: WO 1993-09100 (1993-05-01), None
patent: WO95/02591 (1995-01-01), None
patent: WO 1995-09838 (1995-04-01), None
patent: WO 1995-30647 (1995-11-01), None
patent: WO 1995-35279 (1995-12-01), None
patent: WO 1996-32385 (1996-10-01), None
patent: WO 1997-22618 (1997-06-01), None
patent: WO 1997-26913 (1997-07-01), None
patent: WO 1997-39121 (1997-10-01), None
patent: WO 1997-39125 (1997-10-01), None
patent: WO 1998-22138 (1998-05-01), None
patent: WO98/35945 (1998-08-01), None
patent: WO 1998-33492 (1998-08-01), None
patent: WO 1998-37877 (1998-09-01), None
patent: WO 1999-07402 (1999-02-01), None
patent: WO99/16755 (1999-04-01), None
patent: WO 1999-18987 (1999-04-01), None
patent: WO 1999-25690 (1999-05-01), None
patent: WO 1999-50230 (1999-10-01), None
patent: WO 1999-54485 (1999-10-01), None
patent: WO 00/19994 (2000-04-01), None
patent: WO 2000-20458 (2000-04-01), None
patent: WO 2000-20621 (2000-04-01), None
patent: WO 00/66102 (2000-11-01), None
patent: WO 01/32604 (2001-05-01), None
patent: WO 02/069965 (2002-09-01), None
patent: WO 2003-024937 (2003-03-01), None
patent: WO 2003-053922 (2003-07-01), None
patent: WO 2003-086390 (2003-10-01), None
patent: WO 2004-035061 (2004-04-01), None
patent: WO 2004-046141 (2004-06-01), None
patent: WO 2004-087653 (2004-10-01), None
patent: WO 2005-019185 (2005-03-01), None
Coskun, et al., “The first regio- and diastereoselective synthesis of homochiral perhydroimidazoisoxazoles via the 1,3-dipolar cycloaddition of imidazoline 3-oxides with (1S)-(-)-β-piene,” Tetrahedron: Asymmetry, vol. 12, Iss. 10, pp. 1463-1467 (2001).
Katzenellenbogen et al. (2000) STN International HCAPLUS Database, Columbus, OH. Accession No. 2000:240935, Reg. No. 234093-17-5.
Fink, et al., “Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens,” Chemistry & Biology, vol. 6, Iss. 4, p. 205-219 (1999).
Morgan T.K. et al: “Synthesis and Pharmacological Studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1-71)phenoxy]ethyl]amino]propoxy]phenyl]methan esulfonamide, a novel antiarrhythmic agent with class II and class III activities” Journal of Medicinal Chemistry, vol. 33, No. 4, 1990, pp. 1087-1090, XP002246837 American Chemical Society, Washington, US.
Scozzafava A. et al: “Carbonic anhydrase activators—Part 21” European Journal of Medicinal Chemistry, Editions Scientifique Elsevier, Paris, FR, vol. 35, No. 1, Jan. 2000, pp. 31-39.
Lampe J.W. et al: “Cardiotonic Agents. 6. Histamine Analogues As Potential Cardiovascular Selective H2 Agonists” Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 33, No. 6, 1990, pp. 1688-1697.
International Search Report dated Jul. 7, 2003, for related PCT application PCT/US 03/06749.
Denny W A, “Structure-Activity Relationships for 2-Phenylbenzimidazole—4—Carboxamides, A New Class of Minimal DNA—Intercalating Agents Which May Not Act Via Tapoisomerase II” Journal of Medicinal Chemistry, American Chemical Society, vol. 33 No. 2, pp. 814-819, (1990).
Eriks J C; “Histamine H2—receptor agonists. Synthesis, in vitro pharmacology, and qualitative substituted 4- and 5-(2-aminoethyl) thiazoles”, Journal of Medicinal Chemistry, vol. 35, No. 17, pp. 3239-3248.
Evans D, “Synthesis of a group of 1H-benzimidazoles and their screening for anti-inflammatory activity” European Journal of Medicinal Chemistry, vol. 31, No. 7, pp. 635-642, (1996).
International Search Report for related PCT application PCT/US03/06749 mailed Sep. 29, 2003.
Penning Thomas D, “structure-Activity Relationship Studies on 1-′2-(4- phenylphenoxy) ethyll Pyrrolidine (SC-22716), a Potent Inhibitor of Leukotriene A4 (LTA4) Hydrolase”, Journal of Medicinal Chemistry, American Chemical Society, vol. 43, pp. 721-735, (2000).
Sanfilippo P J: “Synthesis of aryloxyalkylamines. 1. Novel antisecretory agents with H+K+-ATPase inhibitory activity”, Journal of Medicinal Chemistry, vol. 31 No. 9, pp. 1778-1785 (1988).
Sanfilippo Pauline J, “Synthesis of (arytoxy) alkylamines. 2. Novel imidazo-fused heterocycles with calcium channel blocking and local anesthetic activity”, Journal of Medicinal Chemistry, American Chemical Society, vol. 31, pp. 2221-2227, (1988).
Albercio, et al, “Coupling Reagents and Activation” Meth
Andrews Robert C.
Avor Kwasi S.
Chen Xin
Gopalaswamy Ramesh
Guo Xiao-Chuan
Freistein Andrew B.
McKane Joseph K.
Rollins Samuel B.
TransTech Pharma, Inc.
LandOfFree
Azole derivatives and fused bicyclic azole derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azole derivatives and fused bicyclic azole derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azole derivatives and fused bicyclic azole derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3935206